RedHill Biopharma (RDHL) Misses Q2 EPS by 4c

RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $17.6 million versus the consensus estimate of $23.19 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M